EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research

Mohammad Waseem iD, Bi-Dar Wang iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25021093 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mohammad Waseem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA. Hauptthemen laut MEDLINE: Precision Medicine, Prostatic Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH/NIGMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) has been known as the most prevalent cancer disease and the second leading cause of cancer mortality in men almost all over the globe. There is an urgent need for establishment of PCa models that can recapitulate the progress of genomic landscapes and molecular alterations during development and progression of this disease. Notably, several organoid models have been developed for assessing the complex interaction between PCa and its surrounding microenvironment. In recent years, PCa organoids have been emerged as powerful in vitro 3D model systems that recapitulate the molecular features (such as genomic/epigenomic changes and tumor microenvironment) of PCa metastatic tumors. In addition, application of organoid technology in mechanistic studies (i.e., for understanding cellular/subcellular and molecular alterations) and translational medicine has been recognized as a promising approach for facilitating the development of potential biomarkers and novel therapeutic strategies. In this review, we summarize the application of PCa organoids in the high-throughput screening and establishment of relevant xenografts for developing novel therapeutics for metastatic, castration resistant, and neuroendocrine PCa. These organoid-based studies are expected to expand our knowledge from basic research to clinical applications for PCa diseases. Furthermore, we also highlight the optimization of PCa cultures and establishment of promising 3D organoid models for in vitro and in vivo investigations, ultimately facilitating mechanistic studies and development of novel clinical diagnosis/prognosis and therapies for PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineProstatic NeoplasmsMaleHumansProstateOrganoidsEpigenomicsTumor Microenvironment

Stichwörter der Autor:innen

3D modelcastration resistant prostate cancer (CRPC)in vitro and in vivo modelsneuroendocrine prostate cancer (NEPC)organoidsprecision medicineprostate cancer

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA.
  • Hormone Related Cancers Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.

ORCID-Profile: Mohammad Waseem, Bi-Dar Wang

Förderung

  • NIGMS NIH HHS
  • NIH/NIGMS

Zitieren

APA

Waseem, M., & Wang, B. D. (2024). Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021093

Vancouver

Waseem M, Wang BD. Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25021093

BibTeX
@article{Waseem2024,
  author = {Waseem, Mohammad and Wang, Bi-Dar},
  title = {Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25021093}
}
Kostenlos starten →